Acrivon Therapeutics (ACRV) vs NeOnc Technologies (NTHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acrivon Therapeutics (ACRV) has outperformed NeOnc Technologies (NTHI) over the past year, losing 2.6% versus a loss of 76.8%. Acrivon Therapeutics is the larger company by market cap ($81.8 million vs $80.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRV | NTHI |
|---|---|---|
| Share price | $1.91 | $2.78 |
| Market cap | $81.85M | $80.08M |
| 1-day change | +2.14% | +9.88% |
| YTD return | -20.75% | -66.38% |
| 1-year return | -2.55% | -76.79% |
| EPS (TTM) | $-1.91 | $-2.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.56 | $12.09 |
| 52-week low | $1.27 | $2.50 |
| Distance from 52-week high | -46.35% | -77.01% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +502.09% | +511.51% |
| Average volume | 356.18K | 195.17K |
| Shares outstanding | 42.85M | 28.81M |
| Employees | 74 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRV has outperformed NTHI by 74.2 percentage points over the past year.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
ACRV vs NTHI FAQ
Which is bigger, Acrivon Therapeutics or NeOnc Technologies?
Acrivon Therapeutics (ACRV) is larger, with a market capitalization of $81.85M compared with $80.08M for NeOnc Technologies (NTHI).
Which stock has performed better over the past year, ACRV or NTHI?
ACRV returned -2.55% over the past 12 months, compared with -76.79% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are Acrivon Therapeutics and NeOnc Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.